<DOC>
	<DOC>NCT01641952</DOC>
	<brief_summary>This observational, prospective, multicenter study will evaluate the efficacy and safety of MabThera/Rituxan in participants with active rheumatoid arthritis and an inadequate response or intolerance to one anti-TNF therapy. Participants who receive MabThera/Rituxan according to the current standard and in line with the summary of product characteristics at a dose of 1000 milligram (mg) intravenously on Days 1 and 15 will be followed for 20 weeks.</brief_summary>
	<brief_title>An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult participants, &gt;/= 18 years of age Participants with rheumatoid arthritis, eligible for treatment with MabThera/Rituxan in accordance with summary of product characteristics (SPC) Inadequate response to a single TNF inhibitor defined as change in disease activity score28 erythrocyte sedimentation rate (DAS28ESR) &lt;1.2 or DAS28ESR &gt;3.5 at 5 months after first course of antiTNF therapy Participants with a clinical and biological evaluation performed within 12 weeks prior to enrollment may be included More than one previous antiTNF therapies Any other biological therapy apart from the one antiTNF therapy Hypersensitivity to rituximab or any of the excipients or to murine proteins Active severe infections Participants in a severely immunocompromised state Severe heart failure [New York Heart Association (NYHA) Class IV] or severe, uncontrolled cardiac disease Women of childbearing potential not willing to use contraception Pregnant or breastfeeding women Participation in another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>